1116 - Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup.
Saved in:
| Title: | 1116 - Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup. |
|---|---|
| Authors: | Moreno, V. (AUTHOR), Luke, J. (AUTHOR), Gelmon, K. (AUTHOR), Joshua, A.M. (AUTHOR), Varga, A.I. (AUTHOR), Desai, J. (AUTHOR), Markman, B. (AUTHOR), Gomez-Roca, C.A. (AUTHOR), De Braud, F. (AUTHOR), Patel, S.P. (AUTHOR), Carlino, M.S. (AUTHOR), Siu, L.L. (AUTHOR), Curigliano, G. (AUTHOR), Liu, Z. (AUTHOR), Ishii, Y. (AUTHOR), Wind-Rotolo, M. (AUTHOR), Basciano, P. (AUTHOR), Azrilevich, A. (AUTHOR), Tabernero, J. (AUTHOR) |
| Source: | European Urology Supplements. Mar2019, Vol. 18 Issue 1, pe1509-e1510. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 15699056 |
|---|---|
| DOI: | 10.1016/S1569-9056(19)31087-5 |
